Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 17;13:234. doi: 10.1186/s12967-015-0543-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Jiang et al. 2015

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Primitive hematopoietic cells showed a dramatic cell-cycle activation after therapy ahead of leukemic cells. Cell cycle status of primitive hematopoietic cells and leukemic cells in the BM post therapy was analyzed by Ki-67 and Hoechst staining on flow cytometry. CD45.2⁺LK⁺S⁺ cells and leukemic cells post therapy were sorted and the expression patterns of cell-cycle related genes in these cells were examined. CD45.2⁺LK⁺S⁺ cells from normal control and leukemic cells sorted from leukemia-only mice were used as control for either cell type, respectively. a Representative flow cytometry plots of cell-cycle of CD45.2⁺LK⁺S⁻ cells in the BM of normal control and the 1-day treated leukemic mice on different days as indicated. b Representative flow cytometry plots of cell-cycle of CD45.2⁺LK⁺S⁺ cells in the BM of normal control and the 1-day treated leukemic mice on different days. c Representative flow cytometry plots of cell-cycle of leukemic cells in the BM of the 1-day treated leukemic mice on different days. d–f Cell-cycle status of CD45.2⁺LK⁺S⁻ and CD45.2⁺LK⁺S⁺ cells in the BM of normal control and the 1-day treated leukemic mice on different days (n = 3–7). g–i Cell-cycle status of leukemic cells in the BM of the 1-day treated leukemic mice on different days (n = 4–8). j–k Gene expression patterns of CD45.2⁺LK⁺S⁺ cells in the BM of normal control and the 1-day treated leukemic mice on the 3rd and 5th day post therapy. l–n Gene expression patterns of leukemic cells in the BM of the leukemia-only and the 1-day treated leukemic mice on the 1st, 5th, and 12th day post therapy. All data were presented as mean ± SEM. Statistical significance determined as: *p < 0.05; **p < 0.01; ***p < 0.001.